Vicapsys Life Sciences, Inc.

OTC:VICPHealthcare · Biotechnology

Mkt Cap$16.19M

Float9.45M

Shares O/S32.37M

Inst Own-

SI<0.1%

Dilution

CLOSED · Nov 4+0.00%$0.5000

CLOSED · Nov 4

Prev close$0.50000.00%Close$0.5000

VOL1K$ Vol$600RVOL0.32x

Mkt Cap$16.19M

Float9.45M

O/S32.37M

VOL1K sh

$ Vol$600

RVOL0.32×

Inst Own-

SI<0.1%

Dilution

OTC:VICPClosed$0.5000+0.00%

MCap$16.19M

Float9.45M

O/S32.37M

VOL1K sh$ Vol$600RVOL0.32×

SI<0.1%

Inst Own-

Dilution

Historical Data

Date	Open	High	Low	Close	Volume
Nov 4, 2026	0.6000	0.6000	0.2000	0.5000	1,400
Nov 2, 2026	0.2600	0.6000	0.2000	0.5000	5,100
Oct 29, 2026	0.4500	0.4500	0.4500	0.4500	110
Oct 22, 2026	0.3977	0.4000	0.1100	0.4000	5,328
Oct 21, 2026	0.4500	0.4500	0.1001	0.3000	10,850
Oct 16, 2026	0.4000	0.4000	0.4000	0.4000	500
Oct 12, 2026	0.1100	0.4000	0.1100	0.4000	7,370
Oct 8, 2026	0.1102	0.5499	0.1100	0.5499	5,498
Oct 7, 2026	0.7000	0.7000	0.2100	0.4000	7,476
Oct 6, 2026	0.2001	0.7500	0.2001	0.2301	5,252
Oct 2, 2026	0.8000	0.8000	0.2102	0.6500	5,488
Oct 1, 2026	0.5100	0.5100	0.5100	0.5100	1,000
Sep 30, 2026	0.6500	1.10	0.2001	1.10	7,460
Sep 29, 2026	0.8500	1.10	0.8500	1.10	2,501
Sep 28, 2026	0.2323	0.8500	0.2323	0.8500	1,230
Sep 25, 2026	0.2001	0.8500	0.2001	0.7850	6,362
Sep 24, 2026	0.8500	0.8500	0.6000	0.8500	875

Analyst Coverage

No analyst coverage for this companyNo ratings, price targets, or covering firms on file.

Insider Trades

No insider transactions for this companyForeign private issuers and non-reporting entities don't file Form 4/5.

Shareholders

0.0%

Institutional

(0)

0.0%

Insiderⓘ

(0)

18.8%

5%+ Owners

(1)

81.2%

Unattributed (incl. retail)ⓘ

5%+ Beneficial18.8%

Unattributed (incl. retail)81.2%

Top Shareholders

Name	Shares	%	Source
Wildcat Capital Management, LLC · may incl. warrants· filed Mar 2025	6.1M	18.8%	13G

Sources: Form 4, 13D/13GO/S: 32.4M · as of 13 Dec 2024 · SEC cover page

About

Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive VICAPSYN product to market, guiding it through development and commercialization. This product's intended application is within the field of transplantation, specifically for various transplant therapies and associated stem-cell uses.

Additionally, the company is advancing the development of VYBRIN, a compound based on CXCL12. VYBRIN is being investigated for multiple purposes: preventing the formation of post-surgical adhesions following abdominal operations, coating implantable medical devices and other implants to inhibit fibrosis, and promoting wound healing, with a particular emphasis on diabetic ulcers.

The firm, originally incorporated in 1997, transitioned its name from Phage Therapeutics International, Inc. to Vicapsys Life Sciences, Inc. in September 2017.

Its operations are headquartered in Suwanee, Georgia.

Key Metrics

Market Cap$16.19M

Enterprise Value--

P/E Ratio--

Est. Net Cash/Share--

Institutional Ownership-

No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.

SectorHealthcare

IndustryBiotechnology

ExchangeOTC

Country

IPO DateFeb 23, 1998

Shares Outstanding32.37M

Authorized Shares

Float9.45M

52-Week Range

$0.1001$1.50

$0.5000(29th percentile)

Volume

Average Daily Volume4.38K

1.40K today vs 4.38K avg(-68%)

30d Avg

4.38K

60d Avg

4.09K

90d Avg

4.03K

Earnings

Dividend History

No dividend history available

Compliance Status